Global Lung Cancer Surgery Market to Reach US$8.3 Billion by 2030
The global market for Lung Cancer Surgery estimated at US$6.5 Billion in the year 2024, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Thoracotomy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Minimally Invasive Surgery segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 6.5% CAGR
The Lung Cancer Surgery market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
Lung cancer remains one of the most prevalent and deadly cancers worldwide, making effective treatment modalities like surgery crucial in the fight against this disease. Surgery for lung cancer involves the removal of the tumor and surrounding lung tissue where cancer cells may have spread. This approach is generally most effective in the early stages of lung cancer, specifically non-small cell lung cancer (NSCLC), where the tumor is localized and operable. Advances in surgical techniques, including minimally invasive procedures such as video-assisted thoracic surgery (VATS) and robot-assisted surgery, have significantly improved outcomes for patients. These techniques reduce surgical trauma and recovery time, decrease the risk of complications, and can improve the quality of life post-surgery compared to traditional open surgery. As detection methods improve and more lung cancers are diagnosed at an operable stage, the role of surgery in treatment regimens continues to expand.
The landscape of lung cancer surgery has been transformed by technological advancements that allow for more precise and less invasive procedures. Innovations such as robotic surgery provide surgeons with enhanced dexterity and control, enabling them to perform complex dissections and remove tumors with high precision while preserving healthy tissue. Furthermore, intraoperative imaging technologies like real-time CT scans and fluorescence imaging have improved the accuracy of tumor localization and the assessment of resection margins, ensuring that more of the cancerous tissue is removed during the initial surgery. These advancements not only increase the success rate of surgical interventions but also minimize the physical impact on patients, leading to faster recovery times and less postoperative discomfort.
Early detection and personalized treatment approaches are significantly influencing outcomes in lung cancer surgery. The development of low-dose CT screening for high-risk individuals has led to earlier diagnosis of lung cancer, often at a stage when surgical resection is possible and more likely to be curative. Personalized medicine, which involves genetic profiling of tumors to understand their unique characteristics, has also made strides in determining which patients are good candidates for surgery and how they might best respond to additional treatments such as chemotherapy or targeted therapy. This tailored approach helps in strategizing treatment plans that maximize the efficacy of surgery and minimize unnecessary treatments, thereby improving overall patient survival and quality of life.
The growth in the lung cancer surgery market is driven by several factors, encompassing technological advancements, improved detection methods, and an increased emphasis on personalized medicine. Technological innovations in surgical techniques, including minimally invasive and robotic-assisted surgeries, have broadened the range of operable cases and improved patient outcomes, making surgery a more viable option for many patients. Enhanced screening programs have also played a critical role, as they increase the number of early-stage cancers identified, where surgical intervention can be most beneficial. Additionally, as understanding of the genetic basis of lung cancer improves, personalized surgical treatments are becoming more prevalent, allowing for more targeted and effective interventions. These developments, combined with a growing awareness of lung cancer risks and prevention, continue to drive the demand for surgical solutions in the treatment of lung cancer, reflecting a dynamic and evolving marketplace.
SCOPE OF STUDY:TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook